UPC_CoA_405/2024

TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS BY AN INHIBITOR OF COMPLEMENT

BerufungenHauptberufungCourt of AppealAppealCase Closed

Übersicht Entscheidungen Zitate Dokumente Zeitverlauf

Parteien

Kläger

Alexion Pharmaceuticals, Inc.(AstraZeneca Group)

Vertreter: Wolrad Prinz zu Waldeck Und Pyrmont (Freshfields Bruckhaus Deringer); Christopher Stothers (Freshfields Bruckhaus Deringer); Gregor König (Szynka Tilmann von Renesse)

Beklagte

Amgen Technology (Ireland) Unlimited Company(Amgen Group)
Amgen N.V.(Amgen Group)
Amgen GmbH(Amgen Group)
Amgen AB(Amgen Group)
Amgen S.A.S.(Amgen Group)
Amgen S.R.L.(Amgen Group)
Amgen Biofarmacêutica Lda.(Amgen Group)
Amgen Zdravila D.O.O.(Amgen Group)

Vertreter: Tilman Müller-Stoy (Bardehle Pagenberg); Tobias Wuttke (Bardehle Pagenberg); Tim Harris (Osborne Clark)

Richter

Rian Kalden
Patricia Rombach
Ingeborg Simonsson

Patente

EP3167888
EP 3 167 888

CPC-Codes: A61P31/04, A61P25/18, A61P29/02, A61K39/395, A61K2039/505, A61P7/02, A61P25/26, A61P13/02, A61P15/10, A61P17/00, A61P7/00, A61P25/28…

Sektor: Organic Chemistry

Ausgang

PI abgelehnt

Eingereicht: 11. Juli 2024

Erste Entscheidung: —

Sprache: English

The Court of Appeal dismissed Alexion's appeal against the first-instance refusal of provisional measures, upholding the finding that the patent claim could not be corrected by interpretation to remove alleged errors, and confirming that claim 2 of EP 3 167 888 was more likely than not insufficiently disclosed (Article 83 EPC). The provisional measures application was therefore denied.

Im UPC-Register öffnen